Gregory J. Flesher
2021 - Reneo Pharmaceuticals
In 2021, Gregory J. Flesher earned a total compensation of $5.4M as Chief Executive Officer and President at Reneo Pharmaceuticals, a 3,939% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $219,700 |
---|---|
Option Awards | $4,196,725 |
Salary | $475,000 |
Stock Awards | $429,699 |
Other | $48,346 |
Total | $5,369,470 |
Flesher received $4.2M in option awards, accounting for 78% of the total pay in 2021.
Flesher also received $219.7K in non-equity incentive plan, $475K in salary, $429.7K in stock awards and $48.3K in other compensation.
Rankings
In 2021, Gregory J. Flesher's compensation ranked 2,396th out of 12,415 executives tracked by ExecPay. In other words, Flesher earned more than 80.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,396 | 81st |
Manufacturing | 948 | 83rd |
Chemicals And Allied Products | 361 | 85th |
Drugs | 313 | 85th |
Pharmaceutical Preparations | 205 | 87th |
Flesher's colleagues
We found two more compensation records of executives who worked with Gregory J. Flesher at Reneo Pharmaceuticals in 2021.
News
Reneo Pharmaceuticals CEO Gregory Flesher's 2022 pay falls 78% to $1.2M
April 26, 2023
Reneo Pharmaceuticals CEO Gregory Flesher's 2021 pay jumps 3,939% to $5.4M
April 22, 2022
Tokai Pharmaceuticals CEO Gregory Flesher's 2019 pay slips 11% to $843K
March 31, 2020
Tokai Pharmaceuticals CEO Gregory Flesher's 2018 pay slips 2% to $943K
May 15, 2019